文献速递介入妇产影像MRDSA

控释羟考酮改善症状性子宫肌瘤子宫动脉栓塞术后的疼痛管理

Controlled-release oxycodone improves pain management after uterine artery embolisation for symptomatic fibroids.
PubMed 文献 · Clin Radiol · 2017-01-13

该前瞻性随机研究将60例接受子宫动脉栓塞术的症状性子宫肌瘤患者分为标准镇痛组和标准镇痛联合控释羟考酮组,每组30例。联合控释羟考酮组24小时疼痛评分更低(p=0.029),需要吗啡的患者更少(p=0.017),瘙痒更少(p=0.029)。肌瘤体积与24小时盆腔疼痛无相关性(Spearman's ρ=0.02;p=0.881)。

要点

  • 子宫动脉栓塞术围手术期在标准镇痛基础上加用控释羟考酮可降低术后24小时疼痛评分。
  • 加用控释羟考酮组需要吗啡的患者更少,瘙痒发生率更低。
  • 肌瘤体积与栓塞后24小时盆腔疼痛程度无相关性。

核心结论

  • 在子宫动脉栓塞术的标准镇痛基础上加用控释羟考酮可提供更有效的镇痛,表现为24小时内疼痛评分降低、吗啡用量减少及副作用(主要为瘙痒)减少。

研究设计与样本

  • 前瞻性随机对照研究,2009年1月至2010年3月连续纳入60例接受子宫动脉栓塞术的症状性子宫肌瘤女性,随机分为标准镇痛对照组(30例)和标准镇痛联合控释羟考酮组(30例);评估年龄、疼痛、恶心/呕吐、肌瘤体积、住院时间及患者自控镇痛装置中吗啡的使用与剂量,并以MRI测量的肌瘤体积评估其与栓塞后24小时盆腔疼痛的相关性。

诊断标准与关键数值

  • 24小时疼痛评分在控释羟考酮组更低(p=0.029)。
  • 对照组需要吗啡的患者更多(p=0.017),吗啡用量更高(p=0.130)。
  • 控释羟考酮组瘙痒更少(p=0.029)。
  • 肌瘤体积与24小时疼痛无相关性(Spearman's ρ=0.02;p=0.881)。
  • 两组住院时间无差异。

临床应用与阅片要点

  • 原文结论认为,子宫动脉栓塞术标准镇痛加用控释羟考酮可提供更有效的镇痛并减少吗啡用量及瘙痒。
  • 原文未报告肌瘤体积可用于预测栓塞后24小时疼痛程度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate if pre- and post-procedure administration of controlled-release oxycodone (CRO) in combination with standard analgesia improves pain control and decreases the amount of required post-procedure opioids in uterine fibroid embolisation (UFE).

MATERIALS AND METHODS: Between January 2009 and March 2010, 60 consecutive women were prospectively randomised in two groups for UFE: the control group, in which 30 patients underwent the standard anaesthetic procedure and the CRO group, in which 30 patients underwent the standard anaesthetic procedure with the addition of CRO. Age, pain, nausea/vomiting, fibroid volume, length of hospital stay, and use and dose of morphine received via the patient-controlled analgesia (PCA) device in both groups were evaluated to compare the two methods of pain control. Fibroid volume as measured at magnetic resonance imaging (MRI) was evaluated for correlation with post-embolisation pelvic pain over a period of 24 hours.

RESULTS: A significant difference was seen in the pain scores at 24 hours (p=0.029), with less pain in the CRO group. More patients from the control group required morphine (p=0.017), and at higher levels (p=0.130). Pruritus was lower in patients of the CRO group, probably because they received less morphine (p=0.029). No correlation was seen between leiomyoma volume and pain levels over 24 hours (Spearman's ρ=0.02; p=0.881). Length of hospital stay was not different between the two groups.

CONCLUSION: The addition of CRO to standard analgesia for UFE provides more effective analgesia, with a reduction in pain scores in 24 hours, less morphine use, and decreased side effects, mainly pruritus.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Freire GM, Cavalcante RN, Motta-Leal-Filho JM, et al. Controlled-release oxycodone improves pain management after uterine artery embolisation for symptomatic fibroids. Clin Radiol. 2017. PMID: 28093132. doi:10.1016/j.crad.2016.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。